Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma

Genes Chromosomes and Cancer

Volumn 51, Issue 7, 2012, Pages 675-688

  Onvani, Sara ^a,b   Terakawa, Yuzo ^a,c   Smith, Christian ^a   Northcott, Paul ^a   Taylor, Michael ^a,b   Rutka, James ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEASE INHIBITOR KUNITZ TYPE 1; SERINE PROTEASE INHIBITOR KUNITZ TYPE 2; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GENETICS; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DNA MICROARRAY; EXON; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CELL MOVEMENT; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EXONS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTO-ONCOGENE PROTEINS C-MET; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84862828668     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21954     Document Type: Article

References (43)

1. Abounader R, Laterra J. 2005. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7: 436-451.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
3. Cecchi F, Rabe DC, Bottaro DP. 2010. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 46: 1260-1270.
4. Danilkovitch-Miagkova A, Zbar B. 2002. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109: 863-867.
5. Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. 2002. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 277: 14053-14059.
6. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. 2009. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214.
7. Friedrich R, Fuentes-Prior P, Ong E, Coombs G, Hunter M, Oehler R, Pierson D, Gonzalez R, Huber R, Bode W, Madison EL. 2002. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 277: 2160-2168.
8. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. 2004. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-993.
9. Gentile A, Trusolino L, Comoglio PM. 2008. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85-94.
10. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI. 2006. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103: 4046-4051.
11. Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones-Wallace D, Crolla J, Perry R, Lunec J, Pearson A, Ellison D. 2001. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85: 705-712.
12. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G. 2004. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 101: 17198-17203.
13. Guessous F, Li Y, Abounader R. 2008. Signaling pathways in medulloblastoma. J Cell Physiol 217: 577-583.
14. Jeffers MF. 1999. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling. Oncogene 18: 5120-5125.
15. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. 1997. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94: 11445-11450.
16. Kawaguchi T, Qin L, Shimomura T, Kondo J, Matsumoto K, Denda K, Kitamura N. 1997. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 272: 27558-27564.
17. Kong-Beltran M, Stamos J, Wickramasinghe D. 2004. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer cell 6: 75-84.
18. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT. 2008. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 68: 9945-9953.
19. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R. 2008. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3: e3088.
20. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. 2000. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953.
21. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R. 2005. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65: 9355-9362.
22. Liu X, Newton RC, Scherle PA. 2010. Developing c-MET pathway inhibitors for cancer therapy: Progress and challenges. Trends Mol Med 16: 37-45.
23. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. 2003. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
24. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. 2008. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025-1037.
25. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA. 2001. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29: 143-152.
26. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N. 1993. Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 268: 10024-10028.
27. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. 2011. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29: 1408-1414.
28. Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio PM, Di Renzo MF. 1999. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82: 640-643.
29. Park PC, Taylor MD, Mainprize TG, Becker LE, Ho M, Dura WT, Squire J, Rutka JT. 2003. Transcriptional profiling of medulloblastoma in children. J Neurosurg 99: 534-541.
30. Parr C, Sanders AJ, Jiang WG. 2010. Hepatocyte growth factor activation inhibitors - Therapeutic potential in cancer. Anticancer Agents Med Chem 10: 47-57.
31. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
32. Peruzzi B, Bottaro DP. 2006. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660.
33. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
34. Qin L, Denda K, Shimomura T, Kawaguchi T, Kitamura N. 1998. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2. FEBS Lett 436: 111-114.
35. Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer MA. 2005. Outcome of medulloblastoma in children: Long-term complications and quality of life. Neuropediatrics 36: 357-365.
36. Sardi I, Cavalieri D, Massimino M. 2007. Emerging treatments and gene expression profiling in high-risk medulloblastoma. Paediatr Drugs 9: 81-96.
37. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73.
38. Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C. 2005. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol 346: 1335-1349.
39. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. 1997. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 272: 6370-6376.
40. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
41. Szabo R, Hobson JP, List K, Molinolo A, Lin CY, Bugge TH. 2008. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem 283: 29495-29504.
42. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2011 Dec 2. Epub ahead of print.
43. Tong CY, Hui AB, Yin XL, Pang JC, Zhu XL, Poon WS, Ng HK. 2004. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 100( 2 Suppl Pediatrics): 187-193.